Roland B Walter

List of Publications by Year
in descending order

327 papers	13,593 citations	28190 55 h-index	28224 105 g-index
330 all docs	330 docs citations	330 times ranked	11043 citing authors

#	Article	IF	Citations
1	Elihu H. Estey, MD: Leukaemia expert, statistician, and gentle soul (July 15, 1946â€“October 8, 2021). Bone Marrow Transplantation, 2022, 57, 140-142.	1.3	0
2	Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood, 2022, 139, 1694-1706.	0.6	36
3	Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies. Leukemia, 2022, , .	3.3	0
4	Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm. Leukemia, 2022, , .	3.3	0
5	Where do we stand with radioimmunotherapy for acute myeloid leukemia?. Expert Opinion on Biological Therapy, 2022, 22, 555-561.	1.4	2
6	Intensive chemotherapy for acute myeloid leukemia relapse after allogeneic hematopoietic cell transplantation. American Journal of Hematology, 2022, 97, .	2.0	3
7	Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia. Cancer, 2022, 128, 1411-1417.	2.0	8
8	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. HemaSphere, 2022, 6, e676.	1.2	35
9	Utility of theÂTreatment-Related Mortality (TRM)Âscore to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Leukemia, 2022, 36, 1563-1574.	3.3	2
10	Development of [211At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies. Leukemia, 2022, 36, 1485-1491.	3.3	6
11	Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms. Cancers, 2022, 14, 2934.	1.7	2
12	Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility. Haematologica, 2021, 106, 2114-2120.	1.7	4
13	Brief overview of antibodyâ€“drug conjugate therapy for acute leukemia. Expert Opinion on Biological Therapy, 2021, 21, 795-799.	1.4	8
14	Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow. Blood, 2021, 137, 569-572.	0.6	21
15	Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia. Leukemia, 2021, 35, 295-298.	3.3	5
16	Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia. Pharmacoeconomics, 2021, 39, 121-131.	1.7	3
17	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood, 2021, 137, 751-762.	0.6	183
18	Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms. Leukemia and Lymphoma, 2021, 62, 234-238.	0.6	4

#	Article	IF	Citations
19	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*. British Journal of Haematology, 2021, 192, 832-842.	1.2	15
20	Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy. Leukemia, 2021, 35, 2496-2507.	3.3	6
21	Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203. Leukemia and Lymphoma, 2021, 62, 1774-1777.	0.6	0
22	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. Hemato, 2021, 2, 79-88.	0.2	0
23	Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. Leukemia, 2021, 35, 1529-1538.	3.3	48
24	Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML). Leukemia and Lymphoma, 2021, 62, 1532-1535.	0.6	3
25	Outcomes of Hematopoietic Cell Transplantation in Patients with Mixed Response to Pretransplantation Treatment of Confirmed or Suspected Invasive Fungal Infection. Transplantation and Cellular Therapy, 2021, 27, 684.e1-684.e9.	0.6	2
26	Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?. Leukemia, 2021, 35, 3364-3370.	3.3	4
27	Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 27-36.	2.3	4
28	Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy. Leukemia and Lymphoma, 2021, , 1-10.	0.6	2
29	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2021, 138, 2753-2767.	0.6	305
30	Selection of Patients for Individual Acute Myeloid Leukemia Therapies. Hematologic Malignancies, 2021, , 69-75.	0.2	0
31	Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. Blood, 2021, 138, 372-372.	0.6	13
32	Development of Astatine-211 (211At)-Based Anti-CD123 Radioimmunotherapy for Acute Leukemias and Other CD123+ Hematologic Malignancies. Blood, 2021, 138, 3341-3341.	0.6	2
33	Elihu H. Estey, MD: leukemia expert, statistician, and gentle soul (July 15, 1946â€“October 8, 2021). Leukemia, 2021, 35, 3619-3621.	3.3	0
34	Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy. Blood, 2021, 138, 2776-2776.	0.6	0
35	A Gentleman and a Scholar: Elihu H. Estey, MD (1946 â€“2021). , 2021, 18, .		0
36	Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. Leukemia, 2020, 34, 635-639.	3.3	11

#	Article	IF	Citations
37	Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Bone Marrow Transplantation, 2020, 55, 669-672.	1.3	13
38	Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. Bone Marrow Transplantation, 2020, 55, 843-850.	1.3	32
39	Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61, 1158-1167.	0.6	11
40	Need for routine examination of left ventricular ejection fraction in patients with AML. Leukemia, 2020, 34, 1169-1171.	3.3	1
41	Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. Leukemia, 2020, 34, 1701-1705.	3.3	15
42	Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm. Journal of Clinical Oncology, 2020, 38, 4163-4174.	0.8	30
43	Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia. JAMA Oncology, 2020, 6, 1890.	3.4	207
44	Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia. Leukemia and Lymphoma, 2020, 61, 2990-2994.	0.6	9
45	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematology,the, 2020, 7, e601-e612.	2.2	56
46	Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Cancers, 2020, 12, 2339.	1.7	28
47	Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML). Cancers, 2020, 12, 3617.	1.7	7
48	Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leukemia Research, 2020, 95, 106385.	0.4	26
49	Expanding use of CD33-directed immunotherapy. Expert Opinion on Biological Therapy, 2020, 20, 955-958.	1.4	8
50	The Brutonâ€™s tyrosineÂkinaseÂinhibitor ibrutinib abrogates bispecific antibodyâ€•mediated Tâ€•cell cytotoxicity. British Journal of Haematology, 2020, 189, e9-e13.	1.2	3
51	Targeting MCL-1 in hematologic malignancies: Rationale and progress. Blood Reviews, 2020, 44, 100672.	2.8	135
52	The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia. Leukemia, 2020, 34, 2479-2483.	3.3	11
53	Randomized phase 1 study of sequential (â€œprimedâ€) vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm. Leukemia and Lymphoma, 2020, 61, 1728-1731.	0.6	2
54	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. Leukemia, 2020, 34, 1577-1587.	3.3	22

#	Article	IF	Citations
55	Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models. Blood Reviews, 2020, 44, 100679.	2.8	26
56	Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Advances, 2020, 4, 611-616.	2.5	21
57	Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings. Hematology American Society of Hematology Education Program, 2020, 2020, 129-134.	0.9	15
58	Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia. Blood, 2020, 136, 12-13.	0.6	0
59	Independent Associations Between Glomerular Filtration Rate and Serum Bilirubin Level and Early Mortality in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e633-e635.	0.2	0
60	In the Eye of the Beholder: A Conjunctival Lesion in a Woman With Acute Myelogenous Leukemia. Clinical Infectious Diseases, 2019, 68, 525-529.	2.9	0
61	Novel monoclonal antibody-based therapies for acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2019, 32, 116-126.	0.7	14
62	Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?. Current Hematologic Malignancy Reports, 2019, 14, 171-178.	1.2	20
63	Diagnostic utility of bronchoscopy in adults with acute myeloid leukemia and other high-grade myeloid neoplasms. Leukemia and Lymphoma, 2019, 60, 2304-2307.	0.6	2
64	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology, 2019, 37, 1277-1284.	0.8	494
65	Outpatient induction and consolidation care strategies in acute myeloid leukemia. Current Opinion in Hematology, 2019, 26, 65-70.	1.2	14
66	Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission. Bone Marrow Transplantation, 2019, 54, 1511-1514.	1.3	1
67	COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia. Leukemia, 2019, 33, 805-808.	3.3	10
68	Refining AML outcome prediction. Leukemia, 2019, 33, 283-284.	3.3	4
69	Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms. Haematologica, 2019, 104, e143-e146.	1.7	19
70	Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. Blood Reviews, 2019, 34, 26-33.	2.8	38
71	Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. Leukemia, 2019, 33, 554-558.	3.3	8
72	Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTEÂ® AMG 330. Haematologica, 2019, 104, e59-e62.	1.7	12

#	Article	IF	Citations
73	A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leukemia and Lymphoma, 2019, 60, 1023-1029.	0.6	7
74	Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2. Leukemia, 2019, 33, 762-808.	3.3	53
75	Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial. Blood, 2019, 134, 3905-3905.	0.6	7
76	Anti-Apoptotic BCL-2 Family Members Confer Resistance to Calicheamicin-Based Antibody-Drug Conjugate Therapy of Acute Leukemia. Blood, 2019, 134, 2561-2561.	0.6	0
77	Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML. Biology of Blood and Marrow Transplantation, 2018, 24, 1615-1620.	2.0	29
78	Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia, 2018, 32, 1239-1243.	3.3	57
79	Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. Haematologica, 2018, 103, e106-e109.	1.7	19
80	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2018, 131, 1275-1291.	0.6	796
81	Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia, 2018, 32, 2352-2362.	3.3	39
82	Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia. Expert Opinion on Pharmacotherapy, 2018, 19, 865-882.	0.9	16
83	Investigational CD33-targeted therapeutics for acute myeloid leukemia. Expert Opinion on Investigational Drugs, 2018, 27, 339-348.	1.9	61
84	Patient-reported outcomes in acute myeloid leukemia: Where are we now?. Blood Reviews, 2018, 32, 81-87.	2.8	41
85	Quality of life from the perspective of the patient with acute myeloid leukemia. Cancer, 2018, 124, 145-152.	2.0	32
86	A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood, 2018, 131, 387-396.	0.6	131
87	Characterization of SGN-CD123A, A Potent CD123-Directed Antibodyâ€“Drug Conjugate for Acute Myeloid Leukemia. Molecular Cancer Therapeutics, 2018, 17, 554-564.	1.9	85
88	Minimal Residual Disease Testing After Induction Chemotherapy for Acute Myeloid Leukemia: Moving Beyond Prognostication?. Journal of Clinical Oncology, 2018, 36, 1463-1465.	0.8	4
89	Evaluating measurable residual disease in acute myeloid leukemia. Blood Advances, 2018, 2, 1356-1366.	2.5	132
90	CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia. Oncotarget, 2018, 9, 36543-36544.	0.8	3

#	Article	IF	Citations
91	AML Debate: Use Gemtuzumab Ozogamicin in Most AML Patients vs. Use in CBF Patients or Not at All? Pro. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S61-S63.	0.2	0
92	Next-generation sequencing for measuring minimal residual disease in AML. Nature Reviews Clinical Oncology, 2018, 15, 473-474.	12.5	4
93	A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood, 2018, 132, 1125-1133.	0.6	60
94	Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML). Journal of Drug Assessment, 2018, 7, 51-53.	1.1	25
95	Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. American Journal of Hematology, 2018, 93, E49-E52.	2.0	14
96	A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTEÂ®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). Blood, 2018, 132, 25-25.	0.6	61
97	Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium. Blood, 2018, 132, 2710-2710.	0.6	1
98	Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co-Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML. Blood, 2018, 132, 1436-1436.	0.6	10
99	Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203. Blood, 2018, 132, 1403-1403.	0.6	2
100	Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy. Blood, 2018, 132, 284-284.	0.6	30
101	Validation of the AML-QOL: A Quality of Life Instrument for Patients with Acute Myeloid Leukemia and Other Aggressive Myeloid Neoplasms. Blood, 2018, 132, 4822-4822.	0.6	0
102	Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission. Blood, 2018, 132, 5255-5255.	0.6	0
103	Engineering Resistance to CD33-Targeted Immunotherapy in Normal Hematopoiesis By CRISPR/Cas9-Deletion of CD33 Exon 2. Blood, 2018, 132, 2200-2200.	0.6	0
104	2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials. Blood, 2018, 132, 3978-3978.	0.6	0
105	Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica, 2017, 102, 865-873.	1.7	206
106	Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia. Blood, 2017, 129, 2330-2332.	0.6	39
107	Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study. Leukemia, 2017, 31, 2560-2567.	3.3	28
108	Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?. Current Opinion in Hematology, 2017, 24, 132-138.	1.2	10

#	Article	IF	Citations
109	Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia, 2017, 31, 1855-1868.	3.3	181
110	Measurable residual disease testing in acute myeloid leukaemia. Leukemia, 2017, 31, 1482-1490.	3.3	197
111	Flow cytometric demonstration of decrease in bone marrow leukemic blasts after â€˜Day 14â€™ without further therapy in acute myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 2717-2719.	0.6	7
112	Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. Leukemia, 2017, 31, 2347-2354.	3.3	32
113	A Comparison of Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Treated On versus Off Study. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S281.	0.2	0
114	Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes. Journal of Thrombosis and Thrombolysis, 2017, 44, 442-447.	1.0	30
115	The Prognostic Significance of Measurable (â€œMinimalâ€) Residual Disease in Acute Myeloid Leukemia. Current Hematologic Malignancy Reports, 2017, 12, 547-556.	1.2	19
116	Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?. Leukemia, 2017, 31, 2536-2537.	3.3	10
117	Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit. JAMA Oncology, 2017, 3, 374.	3.4	58
118	CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Childrenâ€™s Oncology Group Trial AAML0531. Journal of Clinical Oncology, 2017, 35, 2674-2682.	0.8	120
119	Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes. Blood, 2017, 130, 890-890.	0.6	41
120	Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML.. Journal of Clinical Oncology, 2017, 35, 7016-7016.	0.8	4
121	Determinants of quality of life in patients with acute myeloid leukemia.. Journal of Clinical Oncology, 2017, 35, e18528-e18528.	0.8	2
122	Should acute myeloid leukemia patients with actionable targets be offered investigational treatment after failing one cycle of standard induction therapy?. Current Opinion in Hematology, 2016, 23, 102-107.	1.2	3
123	Reply to C.S. Hourigan et al. Journal of Clinical Oncology, 2016, 34, 2558-2559.	0.8	1
124	Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia. Clinical Cancer Research, 2016, 22, 5829-5838.	3.2	77
125	T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies. Current Hematologic Malignancy Reports, 2016, 11, 311-317.	1.2	5
126	Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?. Leukemia and Lymphoma, 2016, 57, 1205-1207.	0.6	1

#	Article	IF	Citations
127	Effect of measurable (â€˜minimalâ€™) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. Leukemia, 2016, 30, 2080-2083.	3.3	67
128	Outpatient care of patients with acute myeloid leukemia: Benefits, barriers, and future considerations. Leukemia Research, 2016, 45, 53-58.	0.4	38
129	Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. Blood, 2016, 128, 763-773.	0.6	46
130	Measuring quality of life in acute myeloid leukemia: limitations and future directions. Expert Review of Hematology, 2016, 9, 821-823.	1.0	10
131	Antigen-directed therapies: an effective tool in acute myeloid leukemia?. Immunotherapy, 2016, 8, 1153-1156.	1.0	0
132	Phase <scp>II</scp> study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or highâ€risk <scp>MDS</scp>. British Journal of Haematology, 2016, 172, 238-245.	1.2	25
133	SGN-CD33A (Vadastuximab Talirine) followed by Allogeneic Hematopoietic Stem Cell Transplant (AlloHSCT) Results in Durable Complete Remissions (CRs) in Patients with Acute Myeloid Leukemia (AML). Biology of Blood and Marrow Transplantation, 2016, 22, S211-S212.	2.0	4
134	Incorporating measurable (â€˜minimalâ€™) residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. Leukemia and Lymphoma, 2016, 57, 1527-1533.	0.6	7
135	Activity of the oral mitogenâ€activated protein kinase kinase inhibitor trametinib in <scp>RAS</scp>â€mutant relapsed or refractory myeloid malignancies. Cancer, 2016, 122, 1871-1879.	2.0	113
136	Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?. Expert Review of Hematology, 2016, 9, 335-350.	1.0	20
137	Prediction of early death in adults with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2016, 57, 2421-2424.	0.6	7
138	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Diseaseâ€“Based Definition of Complete Remission?. Journal of Clinical Oncology, 2016, 34, 329-336.	0.8	347
139	Pre- and post-transplant quantification of measurable (â€˜minimalâ€™) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia, 2016, 30, 1456-1464.	3.3	153
140	Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid. British Journal of Haematology, 2016, 172, 134-136.	1.2	9
141	Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged â‰¥65 Years with Acute Myeloid Leukemia. Blood, 2016, 128, 102-102.	0.6	40
142	A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). Blood, 2016, 128, 1068-1068.	0.6	1
143	Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML). Blood, 2016, 128, 1071-1071.	0.6	47
144	A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2016, 128, 211-211.	0.6	24

#	Article	IF	Citations
145	Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). Blood, 2016, 128, 215-215.	0.6	25
146	A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML). Blood, 2016, 128, 340-340.	0.6	4
147	Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML). Blood, 2016, 128, 590-590.	0.6	23
148	Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML). Blood, 2016, 128, 591-591.	0.6	35
149	Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age â‰¥ 65 with acute myelogenous leukemia.. Journal of Clinical Oncology, 2016, 34, 7007-7007.	0.8	22
150	A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia.. Journal of Clinical Oncology, 2016, 34, TPS7071-TPS7071.	0.8	2
151	Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia. Oncotarget, 2016, 7, 43281-43294.	0.8	41
152	Prognostic implication of minimal residual disease in AML.. Journal of Clinical Oncology, 2016, 34, 7016-7016.	0.8	0
153	The Role of Notch in Vascular Endothelial Cell-Mediated Protection of AML Precursors from Targeted Therapy. Blood, 2016, 128, 2750-2750.	0.6	0
154	Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly AML or High Risk MDS Patients. Blood, 2016, 128, 5207-5207.	0.6	0
155	CD33 Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study. Blood, 2016, 128, 2743-2743.	0.6	0
156	Rates of CR with and without Measurable Residual Disease after Induction Treatment with "7+3" or Azacitidine/Decitabine for Newly-Diagnosed AML. Blood, 2016, 128, 2792-2792.	0.6	0
157	The Effect of Measurable Residual Disease at the Time of Allogeneic Hematopoietic Cell Transplantation on Outcomes in Patients with Acute Myeloid Leukemia: A Meta-Analysis. Blood, 2016, 128, 2842-2842.	0.6	0
158	A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2016, 128, 4043-4043.	0.6	0
159	Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study. Blood, 2016, 128, 1064-1064.	0.6	0
160	What qualifies as â€œtrueâ€•salvage therapy in acute myeloid leukemia?: CR rates with second salvage depending on type of first salvage. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S191-S192.	0.2	0
161	High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Childrenâ€™s Oncology Group. Journal of Hematology and Oncology, 2015, 8, 115.	6.9	46
162	Antigen-specific immunotherapies for acute myeloid leukemia. Hematology American Society of Hematology Education Program, 2015, 2015, 584-595.	0.9	22

#	Article	IF	Citations
163	Minimal residual diseaseâ€“directed therapy in acute myeloid leukemia. Blood, 2015, 125, 2331-2335.	0.6	41
164	Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. Blood, 2015, 126, 2790-2797.	0.6	46
165	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. Haematologica, 2015, 100, e409-e411.	1.7	10
166	A phase I/II study of oral clofarabine plus lowâ€dose cytarabine in previously treated acute myeloid leukaemia and highâ€risk myelodysplastic syndrome patients at least 60Âyears of age. British Journal of Haematology, 2015, 170, 349-355.	1.2	7
167	The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk. PLoS ONE, 2015, 10, e0135945.	1.1	51
168	Minimal Residual Disease in Acute Myeloid Leukemiaâ€"Current Status and Future Perspectives. Current Hematologic Malignancy Reports, 2015, 10, 132-144.	1.2	31
169	Gâ€CSF <scp>P</scp>riming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm. American Journal of Hematology, 2015, 90, 295-300.	2.0	16
170	Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy. Leukemia, 2015, 29, 1779-1780.	3.3	7
171	Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological Remission. Biology of Blood and Marrow Transplantation, 2015, 21, 373-378.	2.0	30
172	Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia. Haematologica, 2015, 100, e97-e98.	1.7	16
173	Update on Antigen-Specific Immunotherapy of Acute Myeloid Leukemia. Current Hematologic Malignancy Reports, 2015, 10, 65-75.	1.2	12
174	Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia, 2015, 29, 2104-2107.	3.3	50
175	Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2015, 33, 1258-1264.	0.8	223
176	Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research, 2015, 21, 3187-3195.	3.2	18
177	Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. Haematologica, 2015, 100, e254-e256.	1.7	3
178	T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330. Blood Cancer Journal, 2015, 5, e340-e340.	2.8	57
179	Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome. JAMA Oncology, 2015, 1, 1120.	3.4	43
180	How Do Pretransplantation Peripheral Blood Counts Inform Us about Post-Transplantation Outcomes in Acute Myeloid Leukemia?. Biology of Blood and Marrow Transplantation, 2015, 21, 1340-1342.	2.0	0

#	Article	IF	Citations
181	Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed AML or High-Risk MDS. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S11.	0.2	0
182	The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy. Blood Cancer Journal, 2015, 5, e276-e276.	2.8	13
183	Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy. Biology of Blood and Marrow Transplantation, 2015, 21, 559-564.	2.0	58
184	Management of older or unfit patients with acute myeloid leukemia. Leukemia, 2015, 29, 770-775.	3.3	80
185	Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia, 2015, 29, 312-320.	3.3	138
186	Factors associated with early reinduction chemotherapy for adults with acute myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 782-784.	0.6	3
187	Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia, 2015, 29, 137-144.	3.3	183
188	Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia. Blood, 2015, 126, 2569-2569.	0.6	1
189	A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML). Blood, 2015, 126, 324-324.	0.6	26
190	SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML. Blood, 2015, 126, 330-330.	0.6	19
191	Minimal Residual Disease (MRD) As Exploratory Endpoint in a Phase 1 Study of the Anti-CD123 Mab CSL362 Given As Post-Remission Therapy in Adult Acute Myeloid Leukemia (AML). Blood, 2015, 126, 3819-3819.	0.6	9
192	SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML. Blood, 2015, 126, 454-454.	0.6	29
193	Construction and characterization of novel CD33/CD3 tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2015, 33, 7067-7067.	0.8	3
194	Cell Signaling and Resistance to Immunotoxins. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 75-87.	0.1	0
195	Discrepancy in bone marrow blast counts between morphology and flow cytometry and its potential clinical implications.. Journal of Clinical Oncology, 2015, 33, e18031-e18031.	0.8	0
196	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Is It Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. Blood, 2015, 126, 2571-2571.	0.6	1
197	High Expression of Myocyte Enhancer Factor 2C (MEF2C) Is Associated with Adverse Risk Features and Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood, 2015, 126, 2570-2570.	0.6	16
198	Oncology Providers Ability to Prognosticate Patient Outcomes: An Analysis of the Survey on Provider Assessment of Risk (SPAR) Study. Blood, 2015, 126, 5635-5635.	0.6	0

#	Article	IF	Citations
199	Significance of Peri-Transplant Dynamics of Minimal Residual Disease (MRD) in Adults with Acute Myeloid Leukemia (AML) in Morphological Remission Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. Blood, 2015, 126, 173-173.	0.6	0
200	Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 1339-1339.	0.6	0
201	Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia. Clinical Cancer Research, 2014, 20, 2226-2235.	3.2	71
202	Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia. Expert Review of Hematology, 2014, 7, 317-319.	1.0	23
203	The role of CD33 as therapeutic target in acute myeloid leukemia. Expert Opinion on Therapeutic Targets, 2014, 18, 715-718.	1.5	31
204	Non-steroidal anti-inflammatory drugs and cancer risk in women: Results from the Women's Health Initiative. International Journal of Cancer, 2014, 135, 1869-1883.	2.3	52
205	High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leukemia and Lymphoma, 2014, 55, 2817-2821.	0.6	16
206	The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Reviews, 2014, 28, 143-153.	2.8	145
207	Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leukemia Research, 2014, 38, 329-333.	0.4	21
208	Chronic myeloid leukemia in lymphoid blast crisis. European Journal of Haematology, 2014, 92, 458-458.	1.1	0
209	Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia. Leukemia, 2014, 28, 713-716.	3.3	30
210	Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood, 2014, 123, 554-561.	0.6	155
211	Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design. British Journal of Haematology, 2014, 166, 375-381.	1.2	1
212	Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia. Leukemia, 2014, 28, 1969-1977.	3.3	12
213	Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or highâ€grade myelodysplastic syndromes. American Journal of Hematology, 2014, 89, 423-428.	2.0	49
214	Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia Research, 2014, 38, 564-568.	0.4	10
215	Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. Haematologica, 2014, 99, 54-59.	1.7	47
216	Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood, 2014, 123, 2960-2967.	0.6	62

#	Article	IF	Citations
217	First-in Man, Phase 1 Study of CSL362 (Anti-IL3RÎ± / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse. Blood, 2014, 124, 120-120.	0.6	50
218	The Broad Activity of the CD33/CD3 Bispecific BiTEÂ® Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk. Blood, 2014, 124, 266-266.	0.6	1
219	Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood, 2014, 124, 3732-3732.	0.6	1
220	Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML). Blood, 2014, 124, 623-623.	0.6	27
221	Randomized Study of Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) at High Risk of Treatment-Related Mortality. Blood, 2014, 124, 994-994.	0.6	1
222	Correlation between peripheral blood and bone marrow regarding FLT3 ITD and NPM1 mutational status in patients with AML.. Journal of Clinical Oncology, 2014, 32, 7077-7077.	0.8	0
223	A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. Blood, 2014, 124, 3690-3690.	0.6	0
224	Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study. Blood, 2014, 124, 3730-3730.	0.6	1
225	Effect of Allogeneic Hematopoietic Cell Transplant in First Complete Remission on Post-Relapse CR Rate and Survival in Acute Myeloid Leukemia. Blood, 2014, 124, 5257-5257.	0.6	0
226	Prediction of Treatment-Related Mortality in Patients with Relapsed and Refractory Acute Myeloid Leukemia. Blood, 2014, 124, 2277-2277.	0.6	0
227	Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG. Blood, 2014, 124, 3676-3676.	0.6	0
228	The Treatment Related Mortality Score Predicts Early Adverse Events during Intensive Induction Chemotherapy for Acute Myeloid Leukemia (AML). Blood, 2014, 124, 2276-2276.	0.6	0
229	Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplantation, 2013, 48, 630-641.	1.3	90
230	Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: A report from the children's oncology group. American Journal of Hematology, 2013, 88, 694-702.	2.0	11
231	Frequency of Allogeneic Hematopoietic Cell Transplantation Among Patients With High- or Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission. Journal of Clinical Oncology, 2013, 31, 3883-3888.	0.8	42
232	Regular recreational physical activity and risk of hematologic malignancies: results from the prospective VITamins And lifestyle (VITAL) study. Annals of Oncology, 2013, 24, 1370-1377.	0.6	15
233	High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leukemia and Lymphoma, 2013, 54, 202-204.	0.6	4
234	Significance of FAB subclassification of â€œacute myeloid leukemia, NOSâ€• in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood, 2013, 121, 2424-2431.	0.6	97

#	Article	IF	Citations
235	CMV Replication After Allogeneic Hematopoietic Cell Transplantation and Relapse Risk: Evidence for Early Protection Against Relapse in Acute Leukemia and Lymphoma. Biology of Blood and Marrow Transplantation, 2013, 19, S167.	2.0	0
236	Mott cells. European Journal of Haematology, 2013, 90, 83-83.	1.1	3
237	Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study. Leukemia and Lymphoma, 2013, 54, 2534-2536.	0.6	12
238	Height as an Explanatory Factor for Sex Differences in Human Cancer. Journal of the National Cancer Institute, 2013, 105, 860-868.	3.0	58
239	Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicinâ€"Containing Chemotherapy. Clinical Cancer Research, 2013, 19, 1620-1627.	3.2	58
240	A model for prediction of <scp>FLT</scp>3â€<scp>ITD</scp> and <scp>NPM</scp>1 (without) Tj ETQq0 0 0 rgBT /Overlo leukaemia. British Journal of Haematology, 2013, 163, 130-132.	1.2	1
241	Associations between allergies and risk of hematologic malignancies: Results from the VITamins and lifestyle cohort study. American Journal of Hematology, 2013, 88, 1050-1054.	2.0	15
242	A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood, 2013, 121, 4854-4860.	0.6	546
243	CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood, 2013, 122, 1316-1324.	0.6	260
244	SGN-CD33A: a novel CD33-targeting antibodyâ€"drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood, 2013, 122, 1455-1463.	0.6	356
245	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood, 2013, 122, 1813-1821.	0.6	325
246	AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin. PLoS ONE, 2013, 8, e53518.	1.1	39
247	Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Frontiers in Bioscience - Landmark, 2013, 18, 1311.	3.0	55
248	Gemtuzumab Ozogamicin In Combination With Vorinostat and Azacitidine In Older Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML): Final Results From A Phase 1/2 Study. Blood, 2013, 122, 3936-3936.	0.6	2
249	Abstract LB-293: Phase II study of the oral AKT inhibitor, MK-2206, for acute myeloid leukemia (AML) in second relapse.. , 2013, , .		0
250	Outcome Of Patients With Abnl(17p) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 303-303.	0.6	0
251	Phase 2 Study Of Early Discharge and Outpatient Management Of Adult Patients Following Intensive Induction Chemotherapy For MDS and Non-APL AML. Blood, 2013, 122, 2932-2932.	0.6	0
252	Novel Long-Term Co-Culture Approach Identifies Prognostically Important Heterogeneity Of Stem/Progenitor Cell Involvement In Human Acute Myeloid Leukemia. Blood, 2013, 122, 1318-1318.	0.6	0

#	Article	IF	Citations
253	Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia. Clinical Advances in Hematology and Oncology, 2013, 11, 571-7.	0.3	33
254	Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. Haematologica, 2012, 97, 739-742.	1.7	29
255	Reply to F. Ferrara. Journal of Clinical Oncology, 2012, 30, 463-464.	0.8	1
256	Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood, 2012, 119, 6198-6208.	0.6	273
257	Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood, 2012, 119, 3705-3711.	0.6	91
258	Myeloid sarcoma of the heart. Leukemia and Lymphoma, 2012, 53, 2511-2514.	0.6	8
259	SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML. Blood, 2012, 120, 3589-3589.	0.6	6
260	Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study. Haematologica, 2011, 96, 914-917.	1.7	34
261	Cancer Risk Associated with Long-term Use of Acetaminophen in the Prospective VITamins and Lifestyle (VITAL) Study. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2637-2641.	1.1	11
262	Long-Term Use of Acetaminophen, Aspirin, and Other Nonsteroidal Anti-Inflammatory Drugs and Risk of Hematologic Malignancies: Results From the Prospective Vitamins and Lifestyle (VITAL) Study. Journal of Clinical Oncology, 2011, 29, 2424-2431.	0.8	50
263	Vitamin, Mineral, and Specialty Supplements and Risk of Hematologic Malignancies in the Prospective VITamins And Lifestyle (VITAL) Study. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2298-2308.	1.1	26
264	Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 1190-1197.	0.8	351
265	Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment. Journal of Clinical Oncology, 2011, 29, 4417-4424.	0.8	287
266	Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation.. Journal of Clinical Oncology, 2011, 29, 6506-6506.	0.8	10
267	Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization. PLoS ONE, 2011, 6, e24265.	1.1	33
268	Acute Myeloid Leukemia. Emerging Cancer Therapeutics, 2011, 2, 219-237.	0.1	2
269	Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data. Blood, 2011, 118, 1446-1446.	0.6	0
270	Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood, 2010, 116, 2420-2428.	0.6	70

#	Article	IF	Citations
271	Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia, 2010, 24, 1276-1282.	3.3	91
272	Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. Journal of Clinical Oncology, 2010, 28, 1766-1771.	0.8	187
273	High Expression of the Very Late Antigen-4 Integrin Independently Predicts Reduced Risk of Relapse and Improved Outcome in Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2010, 28, 2831-2838.	0.8	35
274	Pretargeted Radioimmunotherapy for Hematologic and Other Malignancies. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 125-142.	0.7	30
275	Quantitative Effect of Age In Predicting Empirically-Defined Treatment-Related Mortality and Resistance In Newly Diagnosed AML: Case Against Age Alone as Primary Determinant of Treatment Assignment. Blood, 2010, 116, 2191-2191.	0.6	11
276	Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).. Blood, 2010, 116, 3806-3806.	0.6	0
277	The power of comparative studies. Leukemia Research, 2009, 33, 610-612.	0.4	4
278	Phosphorylated ITIMs Enable Ubiquitylation of an Inhibitory Cell Surface Receptor. Traffic, 2008, 9, 267-279.	1.3	30
279	Association between plasma thiols and immune activation marker neopterin in stable coronary heart disease. Clinical Chemistry and Laboratory Medicine, 2008, 46, 648-54.	1.4	7
280	ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2. Journal of Leukocyte Biology, 2008, 83, 200-211.	1.5	70
281	Cutaneous Graft-versus-Host Disease: A Guide for the Dermatologist. Dermatology, 2008, 216, 287-304.	0.9	101
282	Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. Blood, 2008, 111, 4813-4816.	0.6	17
283	CD33 expression and P-glycoproteinâ€“mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood, 2007, 109, 4168-4170.	0.6	176
284	Acute, life-threatening hypoglycemia associated with haloperidol in a hematopoietic stem cell transplant recipient. Bone Marrow Transplantation, 2006, 37, 109-110.	1.3	6
285	Functional expression of the CD163 scavenger receptor on acute myeloid leukemia cells of monocytic lineage. Journal of Leukocyte Biology, 2006, 79, 312-318.	1.5	30
286	Relationship between CD33 Expression, P-Glycoprotein-Mediated Drug Efflux, and Clinical Outcome in Patients Treated in Phase II Trials with Gemtuzumab Ozogamicin Monotherapy.. Blood, 2006, 108, 2324-2324.	0.6	3
287	Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicinâ€“induced cytotoxicity. Blood, 2005, 105, 1295-1302.	0.6	144
288	PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. Blood, 2005, 106, 3584-3593.	0.6	52

#	Article	IF	Citations
289	Letter Regarding Article by Vita et al, â€œSerum Myeloperoxidase Levels Independently Predict Endothelial Dysfunction in Humansâ€• Circulation, 2005, 111, e167-8; author reply e167-8.	1.6	2
290	Vitiligo and Pernicious Anemia. New England Journal of Medicine, 2004, 350, 2698-2698.	13.9	5
291	Functional Tetrahydrobiopterin Synthesis in Human Platelets. Circulation, 2004, 110, 186-192.	1.6	26
292	Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-Î³1 in acute myeloid leukemia cells. Leukemia, 2004, 18, 1914-1917.	3.3	16
293	The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood, 2004, 103, 4276-4284.	0.6	87
294	Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans. Intensive Care Medicine, 2003, 29, 337-337.	3.9	19
295	Safety of lumbar puncture for adults with acute leukemia and restrictive prophylactic platelet transfusion. Annals of Hematology, 2003, 82, 570-573.	0.8	68
296	Rapid Detection of Pathogenic Fungi from Clinical Specimens Using LightCycler Real-Time Fluorescence PCR. European Journal of Clinical Microbiology and Infectious Diseases, 2003, 22, 558-560.	1.3	70
297	Impairment of blood rheology by cholestatic jaundice in human beings. Translational Research, 2003, 142, 391-398.	2.4	4
298	Fatal hepatic veno-occlusive disease associated with terbinafine in a liver transplant recipient. Journal of Hepatology, 2003, 38, 373-374.	1.8	11
299	Acute severe anaemia in an elderly patient with hereditary sphaerocytosis. Postgraduate Medical Journal, 2003, 79, 244-244.	0.9	0
300	HMG-CoA Reductase Inhibitors Are Associated with Decreased Serum Neopterin Levels in Stable Coronary Artery Disease. Clinical Chemistry and Laboratory Medicine, 2003, 41, 1314-9.	1.4	27
301	Continuous Infusion of Escalated Doses of Amphotericin B Deoxycholate: An Openâ€Label Observational Study. Clinical Infectious Diseases, 2003, 36, 943-951.	2.9	116
302	Fatal necrotizing fasciitis due to Streptococcus pneumoniae after renal transplantation. Nephrology Dialysis Transplantation, 2003, 18, 195-197.	0.4	16
303	Expression of the hemoglobin scavenger receptor (CD163/HbSR) as immunophenotypic marker of monocytic lineage in acute myeloid leukemia. Blood, 2003, 101, 3755-3755.	0.6	44
304	Multidrug resistance protein attenuates gemtuzumab ozogamicinâ€“induced cytotoxicity in acute myeloid leukemia cells. Blood, 2003, 102, 1466-1473.	0.6	125
305	Critical Role of Interleukin-1Î² for Transcriptional Regulation of Endothelial 6-Pyruvoyltetrahydropterin Synthase. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, e50-3.	1.1	23
306	Near-fatal arrhythmia caused by hyperkalaemia. British Heart Journal, 2002, 88, 578-578.	2.2	3

#	Article	IF	Citations
307	Acidosis induced by lactate, pyruvate, or HCl increases blood viscosity. Journal of Critical Care, 2002, 17, 68-73.	1.0	24
308	Gemcitabine-associated hemolytic-uremic syndrome. American Journal of Kidney Diseases, 2002, 40, e16.1-e16.6.	2.1	76
309	Metastatic squamous cell carcinoma with marked blood eosinophilia and elevated serum interleukin-5 levels. Experimental Hematology, 2002, 30, 1-2.	0.2	15
310	Life-threatening thrombocytopenia associated with acute Epstein-Barr virus infection in an older adult. Annals of Hematology, 2002, 81, 672-675.	0.8	16
311	Tetrahydrobiopterin in the vascular system. Pteridines, 2001, 12, 93-120.	0.5	5
312	Effects of high-altitude exposure on vascular endothelial growth factor levels in man. European Journal of Applied Physiology, 2001, 85, 113-117.	1.2	62
313	Bone marrow involvement in Whipple's disease: rarely reported, but really rare?. British Journal of Haematology, 2001, 112, 677-679.	1.2	28
314	Commercial taxane formulations induce stomatocytosis and increase blood viscosity. British Journal of Pharmacology, 2001, 134, 1207-1214.	2.7	26
315	Establishment and characterization of an arsenic-sensitive monoblastic leukaemia cell line (SigM5). British Journal of Haematology, 2000, 109, 396-404.	1.2	7
316	Influence of parathyroid hormone, calcitonin, 1,25(OH)2 cholecalciferol, calcium, and the calcium ionophore A23187 on erythrocyte morphology and blood viscosity. Translational Research, 2000, 135, 347-352.	2.4	8
317	Systemic Tetrahydrobiopterin (BH₄) Levels and Coronary Artery Disease. Cardiology, 2000, 94, 265-266.	0.6	4
318	Pharmacological Concentrations of Arginine Influence Human Whole Blood Viscosity Independent of Nitric Oxide Synthase Activity in Vitro. Biochemical and Biophysical Research Communications, 2000, 269, 687-691.	1.0	13
319	Influence of nitrovasodilators and endothelin-1 on rheology of human blood in vitro. British Journal of Pharmacology, 1999, 128, 744-750.	2.7	12
320	The nitric oxide synthase cofactor tetrahydrobiopterin reduces allograft ischemia-reperfusion injury after lung transplantation. Journal of Thoracic and Cardiovascular Surgery, 1999, 118, 726-732.	0.4	42
321	Reactivation of herpesvirus infections after vaccinations?. Lancet, The, 1999, 353, 810.	6.3	112
322	Primary Pleomorphic Adenoma of the External Auditory Canal Diagnosed by Fine Needle Aspiration Cytology. Acta Cytologica, 1999, 43, 489-491.	0.7	16
323	Induction of tetrahydrobiopterin synthesis in human umbilical vein smooth muscle cells by inflammatory stimuli. Immunology Letters, 1998, 60, 13-17.	1.1	14
324	Inhalation of the Nitric Oxide Synthase Cofactor Tetrahydrobiopterin in Healthy Volunteers. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 2006-2010.	2.5	10

#	Article	IF	Citations
325	Untroubled musical judgement of a performing organist during early epileptic seizure of the right temporal lobe1Presented in part at the III Herbert von Karajan Symposion: Musikâ€“Gehirnâ€“Computer (Gesellschaft der Musikfreunde in Wien), May 1986.1. Neuropsychologia, 1997, 35, 45-51.	0.7	13
326	Differential Regulation of Constitutive and Inducible Nitric Oxide Production by Inflammatory Stimuli in Murine Endothelial Cells. Biochemical and Biophysical Research Communications, 1994, 202, 450-455.	1.0	47
327	Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia. Leukemia, 0, , .	3.3	1